Detrol Related Published Studies
Well-designed clinical trials related to Detrol (Tolterodine)
Effects of terazosin and tolterodine on ureteral stent related symptoms: a
double-blind placebo-controlled randomized clinical trial. [2013]
Efficacy of tolterodine for medical treatment of intramural ureteral stone with vesical irritability. [2011.06]
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2011.05]
[Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]. [2011.04]
The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia. [2011.04]
[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. [2011.01]
Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. [2011.01]
Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial. [2010.12]
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration. [2010.11]
Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. [2010.10]
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. [2010.10]
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2010.09.21]
[Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients]. [2010.09]
Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women-a randomized controlled trial. [2010.06.29]
Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release. [2010.03]
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. [2010.01]
Comparison of fesoterodine and tolterodine extended release for the treatment of
overactive bladder: a head-to-head placebo-controlled trial. [2010]
The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. [2009.11]
Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. [2009.09]
Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. [2009.09]
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. [2009.09]
[Combination of tolterodine and tamsulosin for benign prostatic hyperplasia] [2009.07]
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. [2009.04]
The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. [2009.03.07]
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. [2009.01.09]
Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. [2009]
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. [2008.11]
Comparison of fesoterodine and tolterodine in patients with overactive bladder. [2008.11]
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. [2008.11]
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. [2008.09]
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. [2008.09]
Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. [2008.06]
Does tolterodine extended release affect the bladder electrical perception threshold? A placebo controlled, double-blind study with 4 and 8 mg in healthy volunteers. [2007.12]
Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. [2007.11]
Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. [2007.04]
Thorough QT study with recommended and supratherapeutic doses of tolterodine. [2007.03]
Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. [2006.12]
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. [2006.11.15]
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. [2006.09]
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. [2006.08]
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. [2006.06]
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. [2006.05]
Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. [2006.04]
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. [2006.03]
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. [2006.03]
Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. [2006.02]
Evaluating the efficacy of the valsalva maneuver on venous cannulation pain: a prospective, randomized study. [2005.10]
High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma. [2005.09.25]
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. [2005.09]
Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. [2005.09]
Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. [2005.08]
Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. [2005.05]
Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. [2005.05]
Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. [2005.04]
Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. [2005]
Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. [2004.12]
Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. [2004.10]
Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. [2004.08]
A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. [2004.07]
Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. [2004.05]
Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. [2004.02]
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. [2004.01]
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. [2004]
Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. [2004]
Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. [2004]
Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. [2003.12]
Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. [2003.11]
Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. [2003.09]
Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. [2003.09]
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. [2003.08]
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. [2003.06]
A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. [2003.02]
Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. [2003.01]
Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. [2002.12]
A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. [2002.09]
Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. [2002.06]
Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. [2002.05]
Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. [2002.05]
Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. [2002]
Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). [2002]
Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. [2002]
The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. [2001.11]
Tolterodine: a clinical review. [2001.10]
Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. [2001.09]
Tolterodine: a safe and effective treatment for older patients with overactive bladder. [2001.06]
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. [2001.06]
A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. [2001.05]
Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. [2001.05]
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. [2001.04]
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. [2001.04]
Food increases the bioavailability of tolterodine but not effective exposure. [2001.03]
Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. [2001.03]
Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. [2001]
Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. [2001]
Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. [1999.05]
Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. [1999.05]
Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. [1999]
Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. [1998.06]
Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. [1998.01]
Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. [1998]
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. [1997.12]
|
